Zobrazeno 1 - 8
of 8
pro vyhledávání: ''
Autor:
Sonali Jindal, Hong Chen, Christopher J. Logothetis, Ana Aparicio, Rebecca S. S. Tidwell, Paul G. Corn, Padmanee Sharma, Bilal A. Siddiqui, Ashwin Varma, James P. Allison, Sumit K. Subudhi, Shalini S. Yadav, Sreyashi Basu
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
BackgroundImmune checkpoint therapy (ICT) has low response rates in patients with metastatic castration-resistant prostate cancer (mCRPC), in part due to few T cells in the tumor microenvironment (TME). Anti-cytotoxic T lymphocyte-associated protein
Autor:
Na Huang, Jianjun Peng, Jiani Wu, Nailin Li, Li Sun, Zilan Ye, Huiying Sun, Yunfang Yu, Jianhua Wu, Jianping Bin, Yong Li, Min Shi, Kyoung-Mee Kim, Xiaoxiang Rong, Jian Xiao, Wangjun Liao, Wenjun Qiu, Rui Zhou, Yulin Liao, Dongqiang Zeng, Gaofeng Wang, Huiyan Luo, Yichen Xue
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundDurable efficacy of immune checkpoint blockade (ICB) occurred in a small number of patients with metastatic gastric cancer (mGC) and the determinant biomarker of response to ICB remains unclear.MethodsWe developed an open-source TMEscore R
Autor:
Sharon Ng, Meenal Sinha, Rahul Aggarwal, Terence W. Friedlander, Christopher Nguyen, Li Zhang, Sumit K. Subudhi, Brandon Chen, E Liu, Alexander Cheung, Padmanee Sharma, Kate Allaire, James P. Allison, Lawrence Fong, Matthew H. Spitzer, Eric J. Small, Jaqueline Marquez
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol 9, iss 5
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol 9, iss 5
BackgroundSipuleucel-T is a US Food and Drug Administration-approved autologous cellular immunotherapy that improves survival in patients with metastatic castration-resistant prostate cancer (mCRPC). We examined whether administering ipilimumab after
Autor:
Angen Liu, Robert L. Ferris, Dan P. Zandberg, Ashley V. Menk, Maria A. Velez, Greg M. Delgoffe, Kristin DePeaux, Daniel P. Normolle
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
The majority of patients with recurrent/metastatic squamous cell carcinoma of the head and neck (HNSCC) (R/M) do not benefit from anti-PD-1 therapy. Hypoxia induced immunosuppression may be a barrier to immunotherapy. Therefore, we examined the metab
Autor:
Yumin Zhao, Teresa Macarulla, Karim A. Benhadji, Rocio Garcia-Carbonero, M. Lanasa, Davide Melisi, Do Youn Oh, Shawn T. Estrem, Michael Man, Antoine Hollebecque, Emiliano Calvo, Leena Gandhi, Susan C. Guba, Anna M. Varghese, Erkut Borazanci, Valeria Merz, Camilla Zecchetto, Emin Avsar, Ivelina Gueorguieva
Publikováno v:
Scientia
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
BackgroundWe assessed the safety, efficacy, and pharmacokinetics of the transforming growth factor beta (TGFβ) receptor inhibitor galunisertib co-administered with the anti-programmed death-ligand 1 (PD-L1) antibody durvalumab in recurrent/refractor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c216b154283f3708f3a9bd07549799f4
https://hdl.handle.net/11351/6613
https://hdl.handle.net/11351/6613
Autor:
Stefan Traint, Sebastian Bauer, Thomas Brodowicz, Gerwin Heller, Katharina Feldmann, Julia Furtner, Gabriele Amann, Rainer Hamacher, Teresa Hatziioannou, Iris M. Noebauer-Huhmann, Leonhard Müllauer, Wolfgang Lamm, Angelika M. Starzer, Erwin Tomasich, Hans-Ulrich Schildhaus, Anna S. Berghoff, Matthias Preusser
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundSome sarcomas respond to immune checkpoint inhibition, but predictive biomarkers are unknown. We analyzed tumor DNA methylation profiles in relation to immunological parameters and response to anti-programmed cell death 1 (anti-PD-1) immune
Autor:
Magali Svrcek, Quentin Letourneur, Toky Ratovomanana, Adrien Buisson, Anna Pellat, François Paye, Lucile Armenoult, Christelle De La Fouchardiere, Thierry André, Romain Cohen, Alex Duval, Mira Ayadi, Matthieu Sarabi, Vincent Jonchère, Pierre Meeus, Raphael Colle
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer, 2021, 9 (2), pp.e001903. ⟨10.1136/jitc-2020-001903⟩
Journal for Immunotherapy of Cancer, BMJ Publishing Group 2021, 9 (2), pp.e001903. ⟨10.1136/jitc-2020-001903⟩
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer, 2021, 9 (2), pp.e001903. ⟨10.1136/jitc-2020-001903⟩
Journal for Immunotherapy of Cancer, BMJ Publishing Group 2021, 9 (2), pp.e001903. ⟨10.1136/jitc-2020-001903⟩
Metastatic colorectal cancers (mCRC) harboring microsatellite instability (MSI) are sensitive to immune checkpoint inhibitors (ICIs), but the mechanisms of resistance to ICIs remain unclear. Dissociated responses in patients with ICI-treated cancer s
Autor:
Ronny Ben-Avi, Abdullah El-Sayes, Ali A. Ashkar, Ana L. Portillo, Marianne V. Chew, Yaron Shargall, Sophie M. Poznanski, Isabella Y. Fan, Eduardo A. Rojas, Tyrah M. Ritchie
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Lung cancer remains the leading cause of cancer death worldwide despite the significant progress made by immune checkpoint inhibitors, including programmed death receptor-1 (PD1)/PD ligand 1 (PDL1)-blockade therapy. PD1/PDL1−blockade has achieved u